Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Epileptic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained~* Age 6-18 years (Weight ≥ 20 kg)~* Clinical diagnosis of epileptic encephalopathy~  * Subject with epilepsy and developmental impairment;~ * Epileptic activity itself contributes to severe cognitive and behavioural impairments~ * Patients will typically have already have trialed at least two standard therapies~* Females of childbearing age:~* Negative urinary pregnancy test at screening~* Agree to use effective contraception for the duration of the study~Exclusion Criteria:~* Inability of a parent or legal guardian to give informed consent for any reason.~* Known hypersensitivity to memantine hydrochloride~* Taking concomitant Amantadine, Ketamine or Dextromethorphan, Cimetidine, Ranitidine, Procainamide, Quinidine, Quinine, Hydrochlorothiazide, Anticholinergics, L-dopa, Anticoagulant,~* Any degree of renal impairment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Memantine Hydrochloride 10 mg Placebo (Type: ACTIVE_COMPARATOR): Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps
- Placebo Memantine Hydrochloride 10 mg (Type: PLACEBO_COMPARATOR): Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps

Based on this trial design, predict the completion outcome and termination type (if applicable).